WallStreetZenWallStreetZen

NASDAQ: CGTX
Cognition Therapeutics Inc Stock

Open Broker Account
$2.67-0.14 (-4.98%)
Updated Dec 5, 2022
CGTX Price
$2.67
Fair Value Price
$4.69
Market Cap
$64.00M
52 Week Low
$1.07
52 Week High
$9.22
P/E
0.24x
P/B
1.63x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$23.55M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.36
Operating Cash Flow
-$8M
Beta
1.09
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CGTX Overview

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R ̣(sigma-2 receptor) complex. The company also intends to develop and advance candidates in the area of synucleinopathies. Cognition Therapeutics was incorporated in 2007 and is headquartered in Purchase, NY.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CGTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CGTX ($2.67) is undervalued by 43.12% relative to our estimate of its Fair Value price of $4.69 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CGTX ($2.67) is significantly undervalued by 43.12% relative to our estimate of its Fair Value price of $4.69 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CGTX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more CGTX due diligence checks available for Premium users.

Be the first to know about important CGTX news, forecast changes, insider trades & much more!

CGTX News

Valuation

CGTX fair value

Fair Value of CGTX stock based on Discounted Cash Flow (DCF)
Price
$2.67
Fair Value
$4.69
Undervalued by
43.12%
CGTX ($2.67) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CGTX ($2.67) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

CGTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0.24x
Industry
14.34x
Market
21.63x
CGTX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CGTX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

CGTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.63x
Industry
4.96x
CGTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CGTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$6.6M
Profit Margin
0%
CGTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$53.6M
Liabilities
$14.2M
Debt to equity
0.36
CGTX's short-term assets ($50.93M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CGTX's short-term assets ($50.93M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CGTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.0k
Investing
-$23.0k
Financing
$869.0k
CGTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CGTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CGTX$64.00M-4.98%0.24x1.63x
APTO$64.42M-4.38%-1.14x1.38x
ABEO$64.58M-5.76%-0.20x4.19x
ASMB$63.41M-0.76%-0.46x0.62x
PASG$63.28M-4.92%-0.39x0.28x

Cognition Therapeutics Stock FAQ

What is Cognition Therapeutics's quote symbol?

NASDAQ: CGTX) Cognition Therapeutics trades on the NASDAQ under the ticker symbol CGTX. Cognition Therapeutics stock quotes can also be displayed as NASDAQ: CGTX.

If you're new to stock investing, here's how to buy Cognition Therapeutics stock.

What is the 52 week high and low for Cognition Therapeutics (NASDAQ: CGTX)?

(NASDAQ: CGTX) Cognition Therapeutics's 52-week high was $9.22, and its 52-week low was $1.07. It is currently -71.04% from its 52-week high and 149.53% from its 52-week low.

How much is Cognition Therapeutics stock worth today?

(NASDAQ: CGTX) Cognition Therapeutics currently has 23,971,042 outstanding shares. With Cognition Therapeutics stock trading at $2.67 per share, the total value of Cognition Therapeutics stock (market capitalization) is $64.00M.

Cognition Therapeutics stock was originally listed at a price of $12.77 in Oct 8, 2021. If you had invested in Cognition Therapeutics stock at $12.77, your return over the last 1 years would have been -79.09%, for an annualized return of -79.09% (not including any dividends or dividend reinvestments).

How much is Cognition Therapeutics's stock price per share?

(NASDAQ: CGTX) Cognition Therapeutics stock price per share is $2.67 today (as of Dec 5, 2022).

What is Cognition Therapeutics's Market Cap?

(NASDAQ: CGTX) Cognition Therapeutics's market cap is $64.00M, as of Dec 6, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cognition Therapeutics's market cap is calculated by multiplying CGTX's current stock price of $2.67 by CGTX's total outstanding shares of 23,971,042.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.